6-(1H-benzo[d]imidazol-2-ylamino)pyridazin-3(2H)-one | 1350848-84-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 6-(1H-benzo[d]imidazol-2-ylamino)pyridazin-3(2H)-one
• 英文别名: 6-(1h-Benzo[d]imidazol-2-ylamino)pyridazin-3(2h)-one；3-(1H-benzimidazol-2-ylamino)-1H-pyridazin-6-one
• CAS: 1350848-84-8
• 化学式: C₁₁H₉N₅O
• 分子量: 227.225
• InChiKey: ILCDNUWJITYEPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  82.2
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-(6'-Chloropyridazinyl-3')-2-benzimidazolylamine 在 溶剂黄146 作用下， 反应 5.0h， 以58%的产率得到6-(1H-benzo[d]imidazol-2-ylamino)pyridazin-3(2H)-one
  参考文献：
  名称：

  Design, synthesis, and evaluation of anti-inflammatory and ulcerogenicity of novel pyridazinone derivatives

  摘要：

  A series of pyridazinone-containing compounds were designed and synthesized as congeners for diclofenac, the most potent and widely used NSAID. The target compounds were evaluated for their anti-inflammatory activity on rat paw edema inflammation model against diclofenac as a reference compound. Seven of the tested compounds demonstrated more than 50% inhibition of carrageenan-induced rat paw edema at a dose 10 mg/kg. The compounds, 6-(2-bromophenylamino)pyridazin-3(2H)-one 2a and 6-(2,6-dimethylphenylamino)pyridazin-3(2H)-one 2e, displayed 74 and 73.5% inflammation-inhibitory activity, respectively, which is comparable to diclofenac (78.3%) at the same dose level after 4 h. The most active compounds as anti-inflammatory agents, 2a, 2e, and 6a, displayed fewer number of ulcers and milder ulcer score than indomethacin in ulcerogenicity screening.

  DOI：

  10.1007/s00044-011-9895-7

文献信息

• Design, synthesis, and evaluation of anti-inflammatory and ulcerogenicity of novel pyridazinone derivatives
  作者：K. A. M. Abouzid、N. A. Khalil、E. M. Ahmed、A. Esmat、A. M. Al-Abd

  DOI：10.1007/s00044-011-9895-7

  日期：2012.11

  A series of pyridazinone-containing compounds were designed and synthesized as congeners for diclofenac, the most potent and widely used NSAID. The target compounds were evaluated for their anti-inflammatory activity on rat paw edema inflammation model against diclofenac as a reference compound. Seven of the tested compounds demonstrated more than 50% inhibition of carrageenan-induced rat paw edema at a dose 10 mg/kg. The compounds, 6-(2-bromophenylamino)pyridazin-3(2H)-one 2a and 6-(2,6-dimethylphenylamino)pyridazin-3(2H)-one 2e, displayed 74 and 73.5% inflammation-inhibitory activity, respectively, which is comparable to diclofenac (78.3%) at the same dose level after 4 h. The most active compounds as anti-inflammatory agents, 2a, 2e, and 6a, displayed fewer number of ulcers and milder ulcer score than indomethacin in ulcerogenicity screening.